The utility of gadoxetic acid-enhanced magnetic resonance imaging in the surveillance for postoperative recurrence of hepatocellular carcinoma

被引:8
|
作者
Kim, Jung Hee [1 ]
Min, Yang Won [1 ]
Gwak, Geum-Youn [1 ]
Paik, Yong Han [1 ]
Choi, Moon Seok [1 ]
Lee, Joon Hyoek [1 ]
Koh, Kwang Cheol [1 ]
Paik, Seung Woon [1 ]
机构
[1] Sungkyunkwan Univ, Dept Med, Samsung Med Ctr, Sch Med, 81 Irwon Dong, Seoul 06351, South Korea
关键词
enhanced MRI; gadoxetic acid; hepatic resection; hepatocellular carcinoma; surveillance; ROW COMPUTED-TOMOGRAPHY; CHRONIC LIVER-DISEASE; TRIPLE-PHASE MDCT; INTRAHEPATIC RECURRENCE; RISK-FACTORS; HISTOPATHOLOGIC FINDINGS; MULTIDETECTOR CT; SPIRAL CT; MRI; RESECTION;
D O I
10.1097/MD.0000000000005666
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This study aimed to investigate the utility of gadoxetic acid-enhanced magnetic resonance imaging (Gd-MRI) in surveillance for recurrent hepatocellular carcinoma (HCC) after hepatectomy. This retrospective study analyzed 147 patients who underwent surveillance with alternating multidetector computed tomography (MDCT) and Gd-MRI after hepatectomy for HCC. The patients were followed-up every 3 months during the first 2 years, and every 6 months thereafter. At each visit, MDCT was performed but once a year (every 12 months), Gd-MRI was performed instead of MDCT. Each HCC recurrence detection rate of MDCT and Gd-MRI was evaluated, and recurrent HCC characteristics were compared according to the detection test. A total of 63 patients had recurrent HCC. Among them, 9 were detected with Gd-MRI and 29 with MDCT. The baseline characteristics of patients with recurrent HCC showed no significant differences according to the detection test. The HCC recurrence detection rate of Gd-MRI and MDCT was 4.8% (9/180) and 4.3% (29/580), respectively, on the per test basis (P=0.764). However, in the population with a follow-up period of =12 months, the detection rate of Gd-MRI and MDCT was 4.3% (7/150) and 1.5% (19/400), respectively (P=0.035). Recurrent HCCs detected with Gd-MRI were smaller than those detected with MDCT (tumor size <2 cm, 100% vs 65.5%, P=0.040). Our data suggest that Gd-MRI has advantages in detecting recurrent HCC after hepatectomy. Surveillance with alternating MDCT and Gd-MRI may identify more recurrent HCC in an early stage than with MDCT alone in patients who received hepatectomy for HCC.
引用
收藏
页数:5
相关论文
共 50 条
  • [21] Gadoxetic acid-enhanced magnetic resonance imaging can predict the pathologic stage of solitary hepatocellular carcinoma
    Yi-Chen Chou
    I-Ha Lao
    Pei-Ling Hsieh
    Ying-Ying Su
    Chee-Wai Mak
    Ding-Ping Sun
    Ming-Jen Sheu
    Hsing-Tao Kuo
    Tzu-Ju Chen
    Chung-Han Ho
    Yu-Ting Kuo
    World Journal of Gastroenterology, 2019, 25 (21) : 2636 - 2649
  • [22] The Usefulness of Gadoxetic Acid-Enhanced Dynamic Magnetic Resonance Imaging in Hepatocellular Carcinoma: Toward Improved Staging
    Sang Hyun Choi
    Jae Ho Byun
    Heon-Ju Kwon
    Hong Il Ha
    So Jung Lee
    So Yeon Kim
    Hyung Jin Won
    Pyo-Nyun Kim
    Annals of Surgical Oncology, 2015, 22 : 819 - 825
  • [23] Utility of Radial Scanning for the Identification of Arterial Hypervascularity of Hepatocellular Carcinoma on Gadoxetic Acid-Enhanced Magnetic Resonance Images
    Narita, Keigo
    Nakamura, Yuko
    Higaki, Toru
    Nishihara, Takashi
    Harada, Kuniaki
    Takizawa, Masahiro
    Shirase, Ryuji
    Bito, Yoshitaka
    Akagi, Motonori
    Honda, Yukiko
    Iida, Makoto
    Awai, Kazuo
    JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, 2021, 45 (03) : 359 - 366
  • [24] Clinical value of gadoxetic acid-enhanced magnetic resonance imaging in surgery for hepatocellular carcinoma - with a special emphasis on early hepatocellular carcinoma
    Matsuda, Masanori
    WORLD JOURNAL OF HEPATOLOGY, 2015, 7 (30) : 2933 - 2939
  • [25] Was Hypervascular Hepatocellular Carcinoma Visible on Previous Gadoxetic Acid-Enhanced Magnetic Resonance Images?
    Ichikawa, Shintaro
    Ichikawa, Tomoaki
    Motosugi, Utaroh
    Sano, Katsuhiro
    Morisaka, Hiroyuki
    Enomoto, Nobuyuki
    Matsuda, Masanori
    Fujii, Hideki
    LIVER CANCER, 2015, 4 (03) : 154 - 162
  • [26] Simplified liver imaging reporting and data system for the diagnosis of hepatocellular carcinoma on gadoxetic acid-enhanced magnetic resonance imaging
    Lyu, Rong
    Hu, Wei-Juan
    Wang, Di
    Wang, Jiao
    Ye, Yu-Bing
    Jia, Ke-Feng
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 16 (06) : 2439 - 2448
  • [27] Ferucarbotran-Enhanced Magnetic Resonance Imaging Versus Gadoxetic Acid-Enhanced Magnetic Resonance Imaging for the Preoperative Detection of Hepatocellular Carcinoma: Initial Experiencele
    Lee, Ji Young
    Kim, Seong Hyun
    Jeon, Yong Hwan
    Lee, Jongmee
    Kim, Min Ju
    Choi, Dongil
    Lee, Won Jae
    JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, 2010, 34 (01) : 127 - 134
  • [28] Role of gadoxetic acid-enhanced liver magnetic resonance imaging in the evaluation of hepatocellular carcinoma after locoregional treatment
    Marco Gatti
    Cesare Maino
    Fatemeh Darvizeh
    Alessandro Serafini
    Eleonora Tricarico
    Alessia Guarneri
    Riccardo Inchingolo
    Davide Ippolito
    Umberto Ricardi
    Paolo Fonio
    Riccardo Faletti
    World Journal of Gastroenterology, 2022, 28 (26) : 3116 - 3131
  • [29] Macrotrabecular-massive hepatocellular carcinoma: imaging identification and prediction based on gadoxetic acid-enhanced magnetic resonance imaging
    Chen, Jie
    Xia, Chunchao
    Duan, Ting
    Cao, Likun
    Jiang, Hanyu
    Liu, Xijiao
    Zhang, Zhen
    Ye, Zheng
    Wu, Zhenru
    Gao, Ronghui
    Shi, Yujun
    Song, Bin
    EUROPEAN RADIOLOGY, 2021, 31 (10) : 7696 - 7704
  • [30] Role of gadoxetic acid-enhanced liver magnetic resonance imaging in the evaluation of hepatocellular carcinoma after locoregional treatment
    Gatti, Marco
    Maino, Cesare
    Darvizeh, Fatemeh
    Serafini, Alessandro
    Tricarico, Eleonora
    Guarneri, Alessia
    Inchingolo, Riccardo
    Ippolito, Davide
    Ricardi, Umberto
    Fonio, Paolo
    Faletti, Riccardo
    WORLD JOURNAL OF GASTROENTEROLOGY, 2022, 28 (26) : 3116 - 3131